Indoleamine 2, 3-dioxygenase 1 (IDO1) inhibitors in clinical trials for cancer immunotherapy

K Tang, YH Wu, Y Song, B Yu - Journal of Hematology & Oncology, 2021 - Springer
Abstract Indoleamine 2, 3-dioxygenase 1 (IDO1) is a heme enzyme that catalyzes the
oxidation of L-tryptophan. Functionally, IDO1 has played a pivotal role in cancer immune …

Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond

M Platten, EAA Nollen, UF Röhrig, F Fallarino… - Nature reviews Drug …, 2019 - nature.com
Abstract l-Tryptophan (Trp) metabolism through the kynurenine pathway (KP) is involved in
the regulation of immunity, neuronal function and intestinal homeostasis. Imbalances in Trp …

Metabolic support of tumour-infiltrating regulatory T cells by lactic acid

MLJ Watson, PDA Vignali, SJ Mullett… - Nature, 2021 - nature.com
Regulatory T (Treg) cells, although vital for immune homeostasis, also represent a major
barrier to anti-cancer immunity, as the tumour microenvironment (TME) promotes the …

Recent update on development of small-molecule STAT3 inhibitors for cancer therapy: from phosphorylation inhibition to protein degradation

J Dong, XD Cheng, WD Zhang… - Journal of Medicinal …, 2021 - ACS Publications
Signal transducer and activator of transcription 3 (STAT3) is a transcription factor that
regulates various biological processes, including proliferation, metastasis, angiogenesis …

Modulation of T cells by tryptophan metabolites in the kynurenine pathway

TW Stone, RO Williams - Trends in Pharmacological Sciences, 2023 - cell.com
Lymphocytes maturing in the thymus (T cells) are key factors in adaptive immunity and the
regulation of inflammation. The kynurenine pathway of tryptophan metabolism includes …

Discovery of IDO1 inhibitors: from bench to bedside

GC Prendergast, WP Malachowski, JB DuHadaway… - Cancer research, 2017 - AACR
Small-molecule inhibitors of indoleamine 2, 3-dioxygenase-1 (IDO1) are emerging at the
vanguard of experimental agents in oncology. Here, pioneers of this new drug class provide …

Targeting the IDO1 pathway in cancer: from bench to bedside

M Liu, X Wang, L Wang, X Ma, Z Gong… - Journal of hematology & …, 2018 - Springer
Abstract Indoleamine 2, 3-dioxygenases (IDO1 and IDO2) and tryptophan 2, 3-dioxygenase
(TDO) are tryptophan catabolic enzymes that catalyze the conversion of tryptophan into …

Coordination Polymer‐Coated CaCO3 Reinforces Radiotherapy by Reprogramming the Immunosuppressive Metabolic Microenvironment

C Wang, Z Dong, Y Hao, Y Zhu, J Ni, Q Li… - Advanced …, 2022 - Wiley Online Library
Radiotherapy is widely exploited for the treatment of a large range of cancers in clinic, but its
therapeutic effectiveness is seriously crippled by the tumor immunosuppression, mainly …

Targeting the IDO1/TDO2–KYN–AhR pathway for cancer immunotherapy–challenges and opportunities

JE Cheong, L Sun - Trends in pharmacological sciences, 2018 - cell.com
Indoleamine 2, 3-dioxygenase 1 (IDO1) and tryptophan 2, 3-dioxygenase 2 (TDO2) catalyze
the commitment step of the kynurenine (KYN) metabolic pathway. Traditionally the …

IDO1 in cancer: a Gemini of immune checkpoints

L Zhai, E Ladomersky, A Lenzen, B Nguyen… - Cellular & molecular …, 2018 - nature.com
Abstract Indoleamine 2, 3-dioxygenase 1 (IDO1) is a rate-limiting metabolic enzyme that
converts the essential amino acid tryptophan (Trp) into downstream catabolites known as …